Results 131 to 140 of about 101,548 (353)

Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. [PDF]

, 2019
Vasoactive intestinal peptide (VIP), a gut peptide hormone originally reported as a vasodilator in 1970, has multiple physiological and pathological effects on development, growth, and the control of neuronal, epithelial, and endocrine cell functions ...
Akiba, Yasutada, Iwasaki, Mari, Kaunitz, Jonathan D   +2 more
core  

Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret. [PDF]

, 2014
Background: Rodents are incapable of emesis and consequently the emetic potential of glucagon-like peptide-1 receptor (GLP-1R) agonists in studies designed to assess a potential blood glucose lowering action of the compound was missed.
A Amato, A Flint, A Rotondo, A Vella, A Wettergren, AD Farmer, AH Barnett, AM Holmes, B Kreymann, BD Kiernan, BP Bullock, C Tourrel, CA Richards, Chi-Kong Yeung, CM Edwards, CR Abbott, David TW Yew, DD De Leon, Ge Lin, GJ Sanger, GM Holmes, GR Morrow, I Billig, I Doweck, INC Lawes, J Kim, JA Kim, JL Iltz, JL Lachey, JM Egan, John A Rudd, JP Gutzwiller, JP Gutzwiller, JP Gutzwiller, K Venkova, KE Mayo, KP Kinzig, L Van Bloemendaal, L Zheng, LL Baggio, LT LaCount, M Reardon, MM Combettes, N Imeryuz, N Percie Du Sert, N Percie du Sert, N Percie Du Sert, NA Gupta, Nathalie Percie Du Sert, NH Greig, P Bhandari, Paul LR Andrews, PJ Gianaros, PJ Shughrue, PL Andrews, R Goke, R Goke, R Shirazi, RM Stern, S Madsbad, SE Ayachi, SE Kanoski, SW Chan, SW Chan, SW Chan, Sze Wa Chan, T Perry, T Tolessa, T Tolessa, V Bucinskaite, Y Wei, Zengbing Lu   +71 more
core   +1 more source

The glucagon‐like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents

Addiction Biology, 2015
The incretin hormone, glucagon‐like peptide 1 (GLP‐1), regulates gastric emptying, glucose‐dependent stimulation of insulin secretion and glucagon release, and GLP‐1 analogs are therefore approved for treatment of type II diabetes.
Daniel Vallöf, P. Maccioni, G. Colombo, M. Mandrapa, Julia Winsa Jörnulf, E. Egecioglu, Jörgen A. Engel, E. Jerlhag   +7 more
semanticscholar   +1 more source

Bioengineered Isoflavone–Probiotic Functional Foods for Sustainable Modulation of Metabolic and Reproductive Health in PCOS

Food Bioengineering, EarlyView.
Synergistic isoflavone‐probiotic action modulated metabolic, microbial and ovarian pathway ABSTRACT Polycystic ovary syndrome (PCOS) is a prevalent metabolic–endocrine disorder characterized by insulin resistance, hyperandrogenism, chronic inflammation, oxidative stress, and ovarian dysfunction, with growing evidence implicating gut microbiota ...
Jeyavelkumaran Renukadevi, Panneerselvam Sneha, Dhanapal Saravanan Mridula, Keerthivasan Nimithasree, Valliappan Sanjay   +4 more
wiley   +1 more source

Signal Transduction and Pathogenic Modifications at the Melanocortin-4 Receptor: A Structural Perspective [PDF]

, 2019
The melanocortin-4 receptor (MC4R) can be endogenously activated by binding of melanocyte-stimulating hormones (MSH), which mediates anorexigenic effects. In contrast, the agouti-related peptide (AgRP) acts as an endogenous inverse agonist and suppresses
Biebermann, Heike, Cerdá-Reverter, José Miguel, Heyder, Nicolas, Kleinau, Gunnar, Krude, Heiko, Kwiatkowski, Dennis, Kühnen, Peter, Scheerer, Patrick, Soletto, Lucia, Speck, David, Szczepek, Michal   +10 more
core   +1 more source

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists

Diabetes Care, 2011
Targeting the incretin system has become an important therapeutic approach for treating type 2 diabetes. Two drug classes have been developed: glucagon-like peptide (GLP)-1 receptor agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors. Clinical data have revealed that these therapies improve glycemic control while reducing body weight (GLP-1 receptor
openaire   +1 more source

Tinjauan atas Glucagon-like peptide-1 receptor agonist

Cermin Dunia Kedokteran, 2020
<p>GLP-1 receptor agonist secara struktur mirip hormon alami GLP-1 yang memiliki efek incretin, namun degradasinya dapat dicegah oleh DPP-4. Saat ini terdapat 8 jenis yang terdiri dari exenatide, exenatide ER, liraglutide, albiglutide, dulaglutide, lixisenatide, semaglutide injeksi, dan semaglitode oral.
openaire   +1 more source

Differential effects of glucagon-like peptide-1 receptor agonists on heart rate [PDF]

, 2017
While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are known to increase heart rate (HR), it is insufficiently recognized that the extent varies greatly between the various agonists and is affected by the assessment methods employed.
A Asmar, A Asmar, A Ceriello, A Gill, A Jorsal, A Jorsal, A Plamboeck, AA Voors, AG Bertoni, Anne Lehmann, B Darpo, B Darpo, B Mendis, BM Scirica, C Perret-Guillaume, C Pyke, Christine Roy-Duval, David Owens, Denis Raccah, DJ Drucker, Francesca Lawson, GS Hillis, GS Hillis, H Linnebjerg, J Can van, J Skov, J Tillner, JA Lovshin, JJ Meier, JJ Meier, JR Ussher, K Swedberg, KB Margulies, KB Margulies, KC Ferdinand, KJ Griffioen, L Blonde, L Ryden, Lawrence Blonde, LE Robinson, LG Trahair, M Kim, M Komajda, M Lorenz, MA Nauck, MA Pfeffer, Martin Lorenz, MT Cooney, P Kumarathurai, P Sager, R Simo, Riccardo Perfetti, RR Holman, SE Inzucchi, SP Marso, T Vilsboll, X Zhou, Y Nakatani   +57 more
core   +1 more source

Exploring the roles and impacts of pharmacists embedded in general practice: a scoping review

Journal of Pharmacy Practice and Research, EarlyView.
Abstract Background The role of the general practice pharmacist (GPP) in Australia is not yet clearly defined, and their clinical expertise remains underutilised in general practice settings. This may be attributed to a limited understanding of pharmacists' capabilities, which can hinder optimal GPP utilisation.
Christel Chandra, Brooke Bevis, Holly Foot, Nazanin Falconer   +3 more
wiley   +1 more source

The Effect of Gut Hormones on Metabolism and Energy Homeostasis

, 2011
The increasing prevalence of obesity, and its associated morbidity and mortality, together with limited treatment options, underscores an urgent need for investigation into effective therapeutic interventions.
Hostomska, Klara, Hostomska, Klara
core   +1 more source